Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Peptides are legal in California when federal law allows the product and the clinician follows California's rules on examinations, scope of practice, pharmacy licensing, and clinic ownership. Here is what the Medical Board, the Board of Pharmacy, and the 2026 legislature add to federal law.
Yes, peptides are legal in California when the product has a lawful federal pathway and the clinician prescribing it meets California's own rules. Federal law decides whether a peptide can reach a patient at all. California then decides who may prescribe it, what examination must come first, which pharmacies may fill it, and who may own the clinic offering it.
That second layer is where most California problems start. A peptide can be a lawful compounded prescription under federal law and still be prescribed unlawfully in California because the exam was skipped, the nurse practitioner had no standardized procedure covering it, or the med spa was owned by someone who cannot own a medical practice.
Status as of October 6, 2026. California has no peptide-specific statute. The rules below are the state's general prescribing, pharmacy, and corporate practice laws as they apply to peptides. For the federal picture (FDA approval, 503A and 503B compounding, FDA's categories, and research use only products), start with our US guide to peptide legality.
| Rule | Source | What it means for peptides |
|---|---|---|
| Appropriate prior exam and medical indication | Business and Professions Code 2242 | No prescription without an exam that meets the standard of care, which can be done by telehealth |
| Telehealth consent | Business and Professions Code 2290.5 | Verbal or written consent to telehealth, documented before care starts |
| NP prescribing | Business and Professions Code 2836.1, 2837.103, 2837.104 | Standardized procedures with a supervising physician, or 103 and 104 NP status |
| PA prescribing | Business and Professions Code 3502.1 | Only within a practice agreement with a supervising physician |
| Sterile compounding shipped into California | Business and Professions Code 4127.2 | Out-of-state pharmacies need a California nonresident sterile compounding license and an annual inspection |
| In-office dispensing | Business and Professions Code 4170 | Prescribers may dispense to their own patients under pharmacy-level labeling and recordkeeping rules |
| Corporate practice of medicine | Business and Professions Code 2400 and 2052 | Lay owners cannot own or control a medical practice, including a med spa |
| Unapproved new drugs | Health and Safety Code 111550 | Selling a new drug without FDA or state approval violates California law as well as federal law |
California makes it unprofessional conduct to prescribe, dispense, or furnish a prescription drug "without an appropriate prior examination and a medical indication." That is Business and Professions Code section 2242, and the Medical Board of California enforces it against physicians who prescribe on request without evaluating the patient.
Every injectable peptide a pharmacy compounds is a prescription drug, so the rule applies to all of them. The statute allows the exam to happen by telehealth, and it does not require a live video visit: self-screening tools or questionnaires can count, provided the exam meets the standard of care. A one-page intake form that leads straight to a peptide order is the kind of exam that is hard to defend when the indication is vague and the evidence is thin.
Telehealth adds one more step. Under section 2290.5, the clinician must tell the patient that care will be delivered by telehealth and obtain verbal or written consent, and that consent has to be documented.
A clinician treating a patient who is physically in California needs a California license, wherever the clinician is located. An out-of-state physician prescribing peptides by telehealth to California patients without a California license is practicing medicine without one.
Physicians (MDs and DOs) may prescribe any prescription drug within the standard of care, including off-label use of FDA-approved peptide drugs and compounded peptides that have a lawful source.
Nurse practitioners have three routes. Most California NPs still furnish drugs under section 2836.1, which requires an active furnishing number and a standardized procedure written with a supervising physician that names the drugs and circumstances covered. The physician must be reachable by phone during the visit but does not need to be on site, and one physician may supervise no more than four NPs. If peptides are not in the standardized procedure, the NP cannot furnish them.
AB 890 created two newer routes. A 103 NP has completed a transition to practice of at least three full-time years or 4,600 hours and may prescribe without standardized procedures, but only in a setting where at least one physician also practices, such as a clinic or medical group. A 104 NP has practiced in good standing as a 103 NP for at least three more years and may work outside those settings, with a referral plan for complex cases and emergencies. January 1, 2026 was the first date NPs could reach 104 status, so independent NP practices offering peptides are new in California this year.
Physician assistants may furnish drugs only as their practice agreement allows, under section 3502.1. The agreement must cover the drugs, the circumstances, and the extent of supervision, and the supervising physician must be reachable when the PA sees the patient.
Registered nurses cannot prescribe. They may administer a peptide on a valid order from a physician, NP, or PA, which is how most clinics staff injection visits. Our course for nurses and NPs covers these scope questions in more depth.
California layers its own pharmacy law on top of federal 503A and 503B rules. The Board of Pharmacy rewrote its compounding regulations to track current USP standards, effective October 1, 2025. Nonsterile compounding now sits in Title 16 of the California Code of Regulations starting at section 1735, and sterile compounding has moved to sections 1736 through 1736.21. The California Medical Association notes that the final regulations apply to Board of Pharmacy licensees and exempt physician practices.
Out-of-state pharmacies face a stricter gate than in many states. A nonresident pharmacy may not ship sterile compounded drugs, which includes every injectable peptide, into California without a separate sterile compounding license under section 4127.2. The Board inspects the pharmacy before issuing or renewing that license and at least once a year, at the pharmacy's cost, and reviews its sterile compounding procedures, recent inspection reports, and a list of what it compounded in the past year. A clinician can look up both the nonresident pharmacy license and the sterile compounding license on the Board of Pharmacy's license search before sending a single prescription.
None of this changes what may be compounded. A California-licensed pharmacy still needs a bulk substance that qualifies under federal law, which for most peptides means FDA's interim categories and the 503A Bulks List. Our breakdown of FDA's July 2026 advisory committee meeting covers where those decisions stand.
California lets a prescriber dispense drugs directly to their own patients under section 4170, with conditions that catch many clinics off guard. The drug must be for a condition the prescriber is treating, the prescriber must dispense it personally rather than through a nurse or assistant, and the label, packaging, and records must meet the same standards a pharmacy follows. Before dispensing, the prescriber must offer a written prescription and tell the patient in writing that they may fill it at a pharmacy instead. A clinic that stocks and sells peptides like a retail counter crosses the statute's line against keeping a shop for retailing prescription drugs.
California enforces the corporate practice of medicine more strictly than most states. Section 2400 states that corporations and other artificial legal entities "shall have no professional rights, privileges, or powers," and section 2052 makes practicing medicine without a license a crime, a charge that can reach whoever directs the medical side of a business.
For peptides, the consequence lands on med spas and wellness clinics. A business owned by a nurse, an aesthetician, or an investor cannot hire a physician to prescribe peptides for its clients, and a physician who lends a license to such a business is exposed to discipline. The common lawful structure is a professional medical corporation, controlled by physicians, that owns the clinical side and contracts with a separate management company for nonclinical work. The management company cannot control medical decisions, set treatment protocols, or decide which patients receive which drugs.
California's Sherman Food, Drug, and Cosmetic Law mirrors federal drug law. Health and Safety Code section 111550 bars anyone from selling, delivering, or giving away a new drug unless FDA or the state has approved it. A peptide sold for injection under a "research use only" label is a new drug without approval, so selling it into California violates state law alongside federal law. The California Department of Public Health's Food and Drug Branch enforces the Sherman Law, independent of FDA's warning letters.
For a California clinician, the practical rule matches the federal one: never prescribe, administer, or supply a research use only product, and document it as a self-sourced exposure when a patient arrives already using one.
California's 2026 session produced one bill aimed squarely at compounded peptides. AB 1990 would have required pharmaceutical-grade bulk substances with certificates of analysis for compounded weight-loss drugs, added recordkeeping rules, and set penalties of $1,000 per dose for illegally compounded product. It passed the Assembly 69 to 1 in May and was held in the Senate Appropriations Committee in August, so it did not become law.
The bill that did pass, SB 1089, which Governor Newsom signed on September 28, 2026, lets the state pursue partnerships to lower the price of at least one FDA-approved GLP-1 drug. It does not touch compounding or peptide prescribing. Expect a version of AB 1990 to return in 2027, and we will update this page when it does.
Run through these checks for each patient, in addition to the federal checklist in our US guide.
Yes, within their authority. An NP working under standardized procedures may furnish a peptide only if the procedure covers it and the NP holds a furnishing number. A 103 NP may prescribe without standardized procedures in a setting where a physician also practices, and a 104 NP may do so independently.
Yes, when a licensed prescriber examines each patient and the medical side is owned and controlled by physicians, usually through a professional medical corporation. A med spa owned by a nonphysician cannot employ a physician to prescribe for its clients.
Only with a California license. California applies its licensing law based on where the patient is located, and telehealth does not change that.
No. Selling a research use only peptide for human use violates California's Sherman Law and federal drug law, and a clinician should never prescribe or administer one.